Jun Jiang

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 10

Top Venues

Cell research

British journal of cancer

BMC cancer

The oncologist

This page only lists publications with an associated author ORCID identifier.

Publications

Xiao-Qing Xie, Yi Yang, Qiang Wang, Hao-Fei Liu, Xuan-Yu Fang, Cheng-Long Li, Yi-Zhou Jiang, Shuai Wang, Hong-Yu Zhao, Jing-Ya Miao, Shuai-Shuai Ding, Xin-Dong Liu, Xiao-Hong Yao, Wen-Tao Yang, Jun Jiang, Zhi-Ming Shao, Guoxiang Jin, Xiu-Wu Bian
Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria. Cell research 33 (3) (2023)
Xiao-Qing Xie, Yi Yang, Qiang Wang, Hao-Fei Liu, Xuan-Yu Fang, Cheng-Long Li, Yi-Zhou Jiang, Shuai Wang, Hong-Yu Zhao, Jing-Ya Miao, Shuai-Shuai Ding, Xin-Dong Liu, Xiao-Hong Yao, Wen-Tao Yang, Jun Jiang, Zhi-Ming Shao, Guoxiang Jin, Xiu-Wu Bian
Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria. Cell research 33 (3) (2023)
Xiao-Qing Xie, Yi Yang, Qiang Wang, Hao-Fei Liu, Xuan-Yu Fang, Cheng-Long Li, Yi-Zhou Jiang, Shuai Wang, Hong-Yu Zhao, Jing-Ya Miao, Shuai-Shuai Ding, Xin-Dong Liu, Xiao-Hong Yao, Wen-Tao Yang, Jun Jiang, Zhi-Ming Shao, Guoxiang Jin, Xiu-Wu Bian
Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria. Cell research 33 (3) (2023)
Xiao-Qing Xie, Yi Yang, Qiang Wang, Hao-Fei Liu, Xuan-Yu Fang, Cheng-Long Li, Yi-Zhou Jiang, Shuai Wang, Hong-Yu Zhao, Jing-Ya Miao, Shuai-Shuai Ding, Xin-Dong Liu, Xiao-Hong Yao, Wen-Tao Yang, Jun Jiang, Zhi-Ming Shao, Guoxiang Jin, Xiu-Wu Bian
Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria. Cell research 33 (3) (2023)
Xiao-Qing Xie, Yi Yang, Qiang Wang, Hao-Fei Liu, Xuan-Yu Fang, Cheng-Long Li, Yi-Zhou Jiang, Shuai Wang, Hong-Yu Zhao, Jing-Ya Miao, Shuai-Shuai Ding, Xin-Dong Liu, Xiao-Hong Yao, Wen-Tao Yang, Jun Jiang, Zhi-Ming Shao, Guoxiang Jin, Xiu-Wu Bian
Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria. Cell research (2023)
Xiao-Qing Xie, Yi Yang, Qiang Wang, Hao-Fei Liu, Xuan-Yu Fang, Cheng-Long Li, Yi-Zhou Jiang, Shuai Wang, Hong-Yu Zhao, Jing-Ya Miao, Shuai-Shuai Ding, Xin-Dong Liu, Xiao-Hong Yao, Wen-Tao Yang, Jun Jiang, Zhi-Ming Shao, Guoxiang Jin, Xiu-Wu Bian
Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria. Cell research (2023)
Xiao-Qing Xie, Yi Yang, Qiang Wang, Hao-Fei Liu, Xuan-Yu Fang, Cheng-Long Li, Yi-Zhou Jiang, Shuai Wang, Hong-Yu Zhao, Jing-Ya Miao, Shuai-Shuai Ding, Xin-Dong Liu, Xiao-Hong Yao, Wen-Tao Yang, Jun Jiang, Zhi-Ming Shao, Guoxiang Jin, Xiu-Wu Bian
Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria. Cell research 33 (3) (2023)
Qiyun Shi, Juncheng Xuhong, Tao Luo, Jia Ge, Feng Liu, Yang Lan, Qingqiu Chen, Peng Tang, Linjun Fan, Li Chen, Yan Liang, Minghao Wang, Ying Hu, Yi Zhang, Xiu-Wu Bian, Xiaowei Qi, Jun Jiang
PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer. British journal of cancer (2022)
Juncheng Xuhong, Xiaowei Qi, Peng Tang, Linjun Fan, Li Chen, Fan Zhang, Xuanni Tan, Wenting Yan, Ling Zhong, Cheng He, Yan Liang, Lin Ren, Minghao Wang, Yi Zhang, Jun Jiang
Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer: A Phase II Clinical Trial. The oncologist 25 (12) (2020)
Shichao Li, Wenting Yan, Xinhua Yang, Li Chen, Linjun Fan, Haoxi Liu, Kun Liu, Yi Zhang, Jun Jiang
Less micrometastatic risk related to circulating tumor cells after endoscopic breast cancer surgery compared to open surgery. BMC cancer 19 (1) (2019)

Jun Jiang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jun Jiang